- Home
- ORGO vs HEQ Comparison
ORGO vs HEQ Comparison
Compare ORGO & HEQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ORGO | HEQ |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 127.6M | 136.8M |
| IPO Year | 2016 | 2010 |
Fundamental Metrics
Financial Performance| Metric | ORGO | HEQ |
|---|---|---|
| Price | $0.99 | $11.47 |
| Analyst Decision | Hold | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $2.00 | N/A |
| AVG Volume (30 Days) | ★ 1.2M | 18.9K |
| Earning Date | 11-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1600.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $564,169,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $37.55 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 17.04 | N/A |
| 52 Week Low | $0.73 | $10.50 |
| 52 Week High | $6.20 | $12.00 |
Technical Indicators
Market Signals| Indicator | ORGO | HEQ |
|---|---|---|
| Relative Strength Index (RSI) | 47.33 | 52.07 |
| Support Level | $0.93 | $11.27 |
| Resistance Level | $2.58 | $11.60 |
| Average True Range (ATR) | 0.10 | 0.21 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 74.39 | 32.50 |
Price Performance
Historical ComparisonAbout ORGO Organogenesis Holdings Inc.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
About HEQ John Hancock Hedged Equity & Income Fund of Beneficial Interest
John Hancock Hedged Equity & Income Fund is a closed-end management investment company. Its investment objective is to provide total return, with a focus on current income and gains, and to include long-term capital appreciation. It invests in various sectors such as financials, consumer discretionary, information technology, energy, healthcare, materials, real estate, consumer staples, short-term investments, and others.